{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016850","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.633566+00:00","generated_at":"2026-06-24T00:43:45.164532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS","bullets":["Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.","Cash at $70.5M; management expects to fund operations into 2024.","FDA cleared IND for Phase 2 kidney transplant trial; first patient dosed in Phase 1b ex-US kidney study.","Positive Phase 2a ALS topline: tegoprubart met safety endpoints; showed target engagement and biomarker reduction.","Orphan Drug Designation granted for tegoprubart in islet cell transplantation; IgAN trial enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016850","json":"https://secwatch.observer/filing/0000950170-22-016850.json","markdown":"https://secwatch.observer/filing/0000950170-22-016850.md","text":"https://secwatch.observer/filing/0000950170-22-016850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/0000950170-22-016850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/eldn-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:43:45.164532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}